Vertex Pharmaceuticals is a leader in cystic fibrosis treatment, with drugs that have generated significant revenue. The company has expanded into other therapeutic areas, winning approval for treatments in blood disorders and pain management. Vertex’s revenue and profit have reached billions of dollars, thanks to its expertise in CF treatment. The company’s CF business remains a key growth driver, with revenue soaring in recent quarters. Vertex is also making progress with Casgevy and Journavx, two other treatments showing promise. Overall, Vertex Pharmaceuticals is a strong biotech stock with growth potential, especially now at a discounted price.

Vertex Pharmaceuticals has developed CFTR modulators that correct the faulty protein made by the CFTR gene, treating almost 95% of CF patients. The company’s commercialized drugs have delivered billions in revenue, and Vertex predicts up to $12 billion for the full year. Vertex is also exploring new candidates to address the remaining 5% of CF patients. With most of its CF manufacturing in the U.S., Vertex is less vulnerable to import tariffs. While there are risks with investing in biotech companies, Vertex’s dominance in CF and growth potential in other areas make it an appealing stock to consider.

Read more at Nasdaq: Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?